We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

56 hedge funds and large institutions have $5.76M invested in Navidea Biopharmaceuticals Inc. in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more call options, than puts

Call options by funds: $24K | Put options by funds: $19K

8% more funds holding

Funds holding: 52 → 56 (+4)

0% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 13

23% less capital invested

Capital invested by funds: $7.5M → $5.76M (-$1.74M)

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
1.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
13
Reduced
13
Closed
–
Calls
$24K
Puts
$19K
Net Calls
+$5K
Net Calls Change
+$18K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$93.4K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$33.6K
3
Wells Fargo
Wells Fargo
California
+$23.9K
4
Jane Street
Jane Street
New York
+$19.9K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$18.4K

Top Sellers

Rank Fund Capital Flow
1
SFS
Sowell Financial Services
Arkansas
-$347K
2
SIM
Spark Investment Management
New York
-$105K
3
Millennium Management
Millennium Management
New York
-$104K
4
TRCT
Tower Research Capital (TRC)
New York
-$18.4K
5
Goldman Sachs
Goldman Sachs
New York
-$15.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.04M +$12.6K +1,490 +0.6%
BlackRock
2
BlackRock
New York
$1.03M +$2.53K +299 +0.2%
HIIFS
3
Harel Insurance Investments & Financial Services
Israel
$328K – – –
SFS
4
Sowell Financial Services
Arkansas
$302K -$347K -40,949 -54%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$298K – – –
BCM
6
Bridgeway Capital Management
Texas
$270K – – –
Jacobs Levy Equity Management
7
Jacobs Levy Equity Management
New Jersey
$190K +$33.6K +3,965 +21%
California Public Employees Retirement System
8
California Public Employees Retirement System
California
$153K – – –
Goldman Sachs
9
Goldman Sachs
New York
$109K -$15.5K -1,827 -12%
Northern Trust
10
Northern Trust
Illinois
$102K – – –
UBS Group
11
UBS Group
Switzerland
$102K +$93.4K +11,021 +918%
Jane Street
12
Jane Street
New York
$81K +$19.9K +2,344 +32%
Morgan Stanley
13
Morgan Stanley
New York
$75K +$1.92K +226 +3%
HighTower Advisors
14
HighTower Advisors
Illinois
$64K -$5.51K -650 -7%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$60K -$4.99K -589 -8%
Creative Planning
16
Creative Planning
Kansas
$48K – – –
SIM
17
Spark Investment Management
New York
$44K -$105K -12,358 -70%
Wells Fargo
18
Wells Fargo
California
$40K +$23.9K +2,822 +141%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$35K +$18.4K +2,169 +101%
State Street
20
State Street
Massachusetts
$32K – – –
SI
21
SII Investments
Wisconsin
$30K – – –
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$29K – – –
Millennium Management
23
Millennium Management
New York
$25K -$104K -12,293 -81%
GWM
24
Greenwich Wealth Management
Connecticut
$25K – – –
GC
25
Guggenheim Capital
Illinois
$23K +$1.18K +139 +5%
1
2 3

NAVB Hedge Fund Activity: Q3 2017 in Review

56 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2017, worth a combined $5.76M — down 23% from $7.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NAVB positions and 0 closed out — a net gain of 5 holders — while 13 added to existing stakes and 13 trimmed.

The largest buyer was UBS Group, adding an estimated $93.4K. The largest seller was Sowell Financial Services, cutting an estimated $347K.

  • 56 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2017, up from 52 in Q2 2017.
  • Funds reported $5.76M of Navidea Biopharmaceuticals Inc. stock for Q3 2017, down 23% quarter-over-quarter.
  • 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2017 and 0 closed out, a net change of +5 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2017 was UBS Group, an estimated $93.4K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q3 2017 was Sowell Financial Services, an estimated $347K sold.

Based on aggregated 13F filings for Q3 2017.